About the Company
gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GRTS News
GRTS Gritstone bio, Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is ...
Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates
Gritstone bio, Inc. (NASDAQ:GRTS) just released its latest yearly results and things are looking bullish. Overall results were decent, with revenues of US$16m beating estimates by54%. Statutory ...
Domino effect around next-generation Covid vaccine trial pushes Gritstone to cut 40% of staff
Gritstone Bio Inc. will cut 94 jobs — or 40% of its workforce — after the delay of a Covid-19 vaccine clinical trial led to a domino effect stopping a payout the Emeryville company had hoped ...
Why Is Gritstone Bio Stock Trading Lower?
Gritstone bio Inc (NASDAQ:GRTS) shares are trading lower after the company announced an approximately 40% reduction of its workforce. The move comes following the recently announced delay of the ...
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
EMERYVILLE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $10.38 million for the quarter ended December 2023, surpassing the Zacks Consensus ...
Gritstone bio Announces Workforce Reduction
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...
Gritstone bio Announces Workforce Reduction
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, ...
Gritstone bio Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...